Introduction
============

Upper urinary tract urothelial carcinoma (UTUC) accounts for approximately 5%-10% of all urothelial tumors \[[@b1-crt-2019-119]\]. The gold standard curative treatments for localized UTUC are radical nephroureterectomy (RNU) with ipsilateral bladder cuff removal for high-risk UTUC cases and either kidney-sparing surgery with single segmental ureterectomy or endoscopic ablation for low-risk cases. Although the adequate surgical control of local tumor results in a long-term survival of \> 80% to 90% \[[@b2-crt-2019-119]\], progression to regional nodal metastases and distant metastases results in estimated 5-year survival rates of \< 30% and \< 10%, respectively \[[@b3-crt-2019-119]\]. These discrepant survival rates between localized and advanced states reflect the insufficient understanding of UTUC pathogenesis due to its rarity.

Studies on UTUC have been conducted for several decades to determine its similarities with urothelial carcinoma of the bladder. Various clinicopathological parameters related to prognoses have been found and used to establish multiple prognostic models to better predict the outcomes of UTUC after surgical therapy \[[@b4-crt-2019-119],[@b5-crt-2019-119]\]. These factors include tumor stage, nuclear grade, positive lymph node status, and therapeutic modalities including intravesical instillation, as well as the heterogeneity and aggressiveness of the UTUC. The association of some factors with prognostic survivals has been confirmed, whereas the involvement of other factors, such as preoperative hydronephrosis and synchronous bladder tumor lesions, remained controversial due to the low tumor prevalence and the different surgical and chemotherapeutic protocols implemented by various institutions and clinicians \[[@b6-crt-2019-119]-[@b8-crt-2019-119]\].

Tissue microarray (TMA) of surgical specimens, and the expression of immunohistochemical tissue markers, may provide important clues to better understand the pathogenetic characteristics of UTUC and identify universal prognostic markers, which will aid in estimating more precise prognoses of UTUC after surgery. Therefore, in this study, 27 potential urothelial carcinoma-related tissue markers from previous urothelial carcinoma-related tissue studies and National Cancer Center bladder cancer panel \[[@b9-crt-2019-119]-[@b26-crt-2019-119]\] were applied immunohistochemically (IHC) to the TMA of specimens from patients with UTUC who underwent RNU, in order to identify any significant prognostic tissue markers of survival, including intravesical recurrence-free survival (IVRFS), disease-free survival (DFS), and overall survival (OS).

Materials and Methods
=====================

1. Patient inclusion criteria and tissue samples
------------------------------------------------

A total of 162 patients with UTUC who underwent RNU including 46 (28.4%) with a previous history of bladder cancer between 2002 and 2016 were selected, and their medical records and surgical specimens were retrospectively reviewed. Patients who had nonurothelial carcinoma histology, history of neoadjuvant chemotherapy, less than 3-month follow-up, and small tumor volume that was inadequate for the preparation of TMA were all excluded. All samples were transitional cell carcinoma specimens and reviewed blindly, retrospectively, and pathologically by an uropathologist (W.S.P.) with 15 years of experience in accordance with the 2009 tumor, node, and metastasis (TNM) classification for UTUC and the 2004 World Health Organization (WHO)/International Society of Urologic Pathologists (ISUP) consensus classification \[[@b10-crt-2019-119]\].

2. IHC and assessment of TMA
----------------------------

TMA and IHC assessments were performed in accordance with previously published study using TMAs \[[@b26-crt-2019-119]\]. TMA blocks were built using two representative tumor areas (2-mm core) and paired single normal control tissue from formalin-fixed, paraffin-embedded tumor material, and marked on standard hematoxylin and eosin--stained sections for the expressions of tissue markers \[[@b27-crt-2019-119]\].

The following 27 tissue biomarkers in the UTUC TMA were IHC stained: carbonic anhydrase (CA8 and CA9), platelet and endothelial cell adhesion molecule 1/CD31, epidermal growth factor receptor/erythroblastosis oncogene B (C-erb), cytokeratin (CK20 and CK5 & 6), c-Myc, mitochondrially encoded cytochrome c oxidase II (COX2), epithelial cadherin 1 (E-cadherin), excision repair cross-complementation group 1 (ERCC1), hypoxia-inducible factor (HIF-1α and HIF-2α), high-molecular-weight heparin (HMWCK) and low-molecular-weight heparin, programmed cell death 1 ligand (PD-L1), folate hydrolase 1/prostate-specific membrane antigen 1, phosphatase and tensin homolog, retinoblastoma protein (Rb), Ki-67, p53, cyclin D1 and D2, CD34 and 44, smooth muscle actin (SMA), and vascular endothelial growth factor A. The staining condition was validated using negative and positive tissue controls for all antibodies ([S1](#SD1-crt-2019-119){ref-type="supplementary-material"} and [S2 Tables](#SD2-crt-2019-119){ref-type="supplementary-material"}).

3. Interpretation of IHC expression on TMA
------------------------------------------

As described in the previously published study \[[@b26-crt-2019-119]\], the percentage of cells stained (0%-100%) and the staining intensity were assessed within the nuclei and cytoplasm of malignant cells, and compared with those of the paired benign cells. The intensity of CD8 and SMA expression in the tumor environment was assessed. The cases were identified pathologically by a senior uropathologist (W.S.P.) blinded to the clinical outcome using the semi-quantitative H-score (0-300), including the three-tier grading intensity score (0 for negative, 1+ for weak, 2+ for moderate, and 3+ for strong). The intensity score was classified into two categories (negative \[0-1\] or positive \[2-3\]) to examine the concordance rate of the expressions of markers between different organs ([Fig. 1](#f1-crt-2019-119){ref-type="fig"}) and different sites of the same organ ([S1 Table](#SD1-crt-2019-119){ref-type="supplementary-material"}).

4. Statistical analysis
-----------------------

To examine the prognostic value of all 27 tissue biomarkers in terms of OS, DFS, and IVRFS, previously identified clinicopathological variables associated with prognosis were analyzed using a Cox proportional hazards model by a single medical statistician (B.P.). The IVRFS was defined as the free tumor status within the bladder and the DFS as the free disease status from the curative surgery until the detection of progression of the disease or recurrence of disease beyond the intravesical recurrence. The continuous tissue biomarkers were categorized into a binary group (low, high) using a cutoff value determined using the Contal and O'Quigley method \[[@b28-crt-2019-119]\]. After examining the significance of clinicopathological variables in the univariate model ([S3 Table](#SD3-crt-2019-119){ref-type="supplementary-material"}), four variables (age, intravesical instillation, ISUP, and pathologic \[pT\] category) were included in a multivariable clinicopathological model, and the final adjusted parameters were determined using a backward variable selection methodwith an elimination criterion of 0.10. After adjusting for significant clinicopathological variables, the 27 tissue biomarkers were respectively evaluated in the final multivariable model for IVRFS, DFS, and OS ([S3](#SD3-crt-2019-119){ref-type="supplementary-material"} and [S4 Tables](#SD4-crt-2019-119){ref-type="supplementary-material"}). The results were presented as hazard ratios (HR) with their 95% confidence intervals (CI). The survival curves were plotted using survival probability estimated from the final multivariable model. p-values of less than 0.05 were considered significant. All statistical analyses were performed using SAS ver. 9.4 (SAS Institute Inc., Cary, NC).

5. Ethical statement
--------------------

This retrospective study was approved by the Institutional Review Board of the National Cancer Center (IRB No. NCC 2018-0166), and the requirement for informed consent was waived owing to the retrospective nature of the study. All patient data were anonymized and de-identified prior to our analysis. All study protocols were performed in accordance with the tenets of the Declaration of Helsinki.

Results
=======

The mean±standard deviation age of the patients was 66.5±10.4 years (men, 119, 73.5%). The rate of pathologic Tis, Ta, and T1 was 22.0% (n=35), while those of pN1-pT2 cateogry and higher ISUP nuclear grade were 8.1% (n=13) and 78.9% (n=120), respectively. There were 72 patients (44.4%) who received adjuvant chemotherapy after surgery. Within a median follow-up of 53.4 (range, 3.6 to 176.5 months), patients with intravesical recurrence (58 cases, 35.8%), disease recurrence beyond the bladder (48 cases, 29.6%), and all cause death (19 cases, 11.7%) including six cancer-specific deaths (31.6%) were identified. The remaining clinicopathological characteristics of the patients and the results of IHC staining for each tissue biomarker are summarized in [Table 1](#t1-crt-2019-119){ref-type="table"} and [S1 Table](#SD1-crt-2019-119){ref-type="supplementary-material"}, respectively.

According to the univariable analysis, the clinicopathological parameters associated with survival prognosis in terms of IVRFS were intravesical instillation after surgery (HR, 22.08; 95% CI, 9.96 to 48.94), ISUP nuclear grade (low vs. high; HR, 0.57; 95% CI, 0.33 to 0.98), and pathologic T category (pTa, pT1, and pTis vs. pT2-pT4; HR, 0.49; 95% CI, 0.28 to 0.84). With regard to DFS, intravesical instillation (HR, 0.22; 95% CI, 0.10 to 0.49), ISUP nuclear grade (low vs. high; HR, 3.02; 95% CI, 1.19 to 7.68), and pathologic T category (pTa, pT1, and pTis vs. pT2-pT4; HR, 8.72; 95% CI, 2.11 to 35.95) were significant risk factors. As regards OS, pathologic T category (pTa, pT1, and pTis vs. pT2-pT4; HR, 6.83; 95% CI, 0.91 to 51.35) only showed significant tendency ([S3 Table](#SD3-crt-2019-119){ref-type="supplementary-material"}). After four significant prognostic variables (age, intravesical instillation, ISUP, and pT category) were included in the multivariable model with tissue markers, only intravesical instillation in the IVRFS model, intravesical instillation (HR, 0.27; 95% CI, 0.12 to 0.59; p=0.001) and pT category (HR, 6.54; 95% CI, 1.58 to 27.16; p=0.010) in the DFS model, and pT stage in the OS model remained significant ([S3 Table](#SD3-crt-2019-119){ref-type="supplementary-material"}).

With regard to the significant tissue markers for each survival model ([Table 2](#t2-crt-2019-119){ref-type="table"}), IVBRFS was associated with E-cadherin (HR, 0.49; 95% CI, 0.26 to 0.91), c-erb (HR, 2.59; 95% CI, 1.05 to 6.39), and Rb loss (HR, 1.85; 95% CI, 1.07 to 3.19) ([Table 2](#t2-crt-2019-119){ref-type="table"}); DFS was associated with cyclin D1 (HR, 2.16; 95% CI, 1.19 to 3.94) and HMWCK (HR, 0.42; 95% CI, 0.22 to 0.79) ([Table 2](#t2-crt-2019-119){ref-type="table"}); and OS was associated with E-cadherin (HR, 0.34; 95% CI, 0.12 to 0.94) and PD-L1 (HR, 13.42; 95% CI, 3.64 to 49.43) in multivariable models including the tissue marker intensity scores (either low or high) of the enrolled patients (p \< 0.05) ([Table 2](#t2-crt-2019-119){ref-type="table"}). The Kaplan-Meier survival curves also showed significant differences between the two groups with different expression levels for c-erb, E-cadherin, and Rb loss for IVRFS ([Fig. 2A](#f2-crt-2019-119){ref-type="fig"}); cyclin D1 and HMWCK for DFS ([Fig. 2B](#f2-crt-2019-119){ref-type="fig"}); and E-cadherin and PD-L1 for OS ([Fig. 2C](#f2-crt-2019-119){ref-type="fig"}) (p \< 0.05).

An additional subgroup analysis was conducted among 111 patients with no prior or concurrent bladder cancer history, to determine the significant prognostic tissue markers associated with IVRFS, DFS, and OS. Results showed that there was a significant difference in the tissue analysis results of all patients ([Table 3](#t3-crt-2019-119){ref-type="table"}). The multivariable analyses of the tumor marker expression levels (either high or low) showed that none of these markers had significant predictive power in IVRFS after adjusting for intravesical instillation. Whereas only cyclin D1 (HR, 2.1; 95% CI, 1.07 to 4.10) and HMWCK (HR, 0.48; 95% CI, 0.24 to 0.99) in DFS, after adjusting for intravesical instillation, and PD-L1 (HR, 11.27; 95% CI, 2.95 to 43.02) and E-cadherin (HR, 0.35; 95% CI, 0.12 to 0.99) in OS, after adjusting for pathologic T category remained significant factors (p \< 0.05).

Discussion
==========

The therapeutic, prognostic, and postoperative follow-up modalities including neo/adjuvant protocols of UTUC were similar to those of bladder-originated urothelial carcinoma. However, the natural history and etiology of UTUC differed from those of bladder cancer with more invasive diagnostic protocols and poorer survival outcomes \[[@b1-crt-2019-119]\]. More prognostic factors including postoperative pathologic stage, grade, lymph node invasion, lymphovascular invasion, and tumor location have been identified for UTUC than for bladder cancer. Meanwhile, the presence of previous bladder cancer history distinguished UTUC from bladder cancer \[[@b4-crt-2019-119],[@b5-crt-2019-119],[@b10-crt-2019-119],[@b14-crt-2019-119],[@b17-crt-2019-119],[@b29-crt-2019-119]\].

Recent studies with TMA of RNU specimens have attempted to define more stratified and precise classification methods based on tissue and genetic markers similar to other cancers \[[@b10-crt-2019-119],[@b21-crt-2019-119]\]. Immunohistochemistry using TMA was widely used to better predict the therapeutic outcome of surgical and systemic medical interventions \[[@b9-crt-2019-119]\]. More accurate subtyping of multi-heterogeneous and mutated cancers has resulted from the understanding of biopsied and surgical tissues obtained from patients with cancer and the expression of each tissue marker in these specimens. This leads to the possibility of individualizing treatment options according to the molecular profile of the tumor, thus increasing prognostic survival and curative rate.

This study investigated the significant tissue markers of three prognostic outcomes (intravesical recurrence, disease recurrence beyond the bladder, and death) with adjustment for the significant prognostic clinicopathological parameters among the 162 patients with and without previous bladder cancer history and several potential prognostic tissue markers among the selected 27 known tissue markers relating to UTUC, bladder urothelial carcinoma, and known therapeutic targets such as checkpoint inhibitors, even after adjustment for the significant prognostic clinicopathological parameters (p \< 0.05) ([Tables 2](#t2-crt-2019-119){ref-type="table"} and [3](#t3-crt-2019-119){ref-type="table"}, [Fig. 2](#f2-crt-2019-119){ref-type="fig"}). In the sub-analyses, about 46 patients with a previous history of bladder cancer also showed some useful prognostic markers of survivals even after adjusting for TMA (p \< 0.05) ([Table 3](#t3-crt-2019-119){ref-type="table"}).

Previous studies showed that cyclin D1 was a significant predictor for DFS in patients with bladder urothelial carcinoma and UTUC \[[@b10-crt-2019-119],[@b11-crt-2019-119]\]. Moreover, it played an important role in the early onset of urothelial tumorigenesis, driving cell proliferation and infiltration \[[@b10-crt-2019-119]\], and was correlated with prognostic clinicopathological parameters, such as TNM stage and nuclear grade, in bladder urothelial carcinoma \[[@b11-crt-2019-119]\]. Additionally, cyclin D1 was significantly associated with tumor recurrence, thus decreasing DFS \[[@b12-crt-2019-119]\]. By contrast, this study also showed that cyclin D1 was associated with DFS (HR, 2.16; p=0.011) ([Table 2](#t2-crt-2019-119){ref-type="table"}).

PD-L1 marker is target receptor in the tumor cell membrane and tumor-infiltrating mononuclear cells to anti--PD-L1 checkpoint inhibitor, and it was shown to be a significantly strong marker for OS (HR, 13.42) in this study ([Table 2](#t2-crt-2019-119){ref-type="table"}), similar to the report of other published studies \[[@b12-crt-2019-119]-[@b14-crt-2019-119]\]. The PD-1/PD-L1 pathway has been highlighted since the last decade; that tumor cells can evade the host immune surveillance through the overexpression of the checkpoint ligands on tumor cells such as PD-L1 \[[@b13-crt-2019-119],[@b14-crt-2019-119]\]. This immune suppressing operation of cancer cells involve immune cell intrinsic checkpoint ligands that are induced on the surface of activated T cells resulting in T-cell dysfunction, which impairs anti-tumor immunity. Many immune agents have been developed in clinical use for many malignancies, resulting in improved prognostic survivals.

The current immune checkpoint inhibitor targeting the PD-L1 expression has proven its potential therapeutic effect with longer survival in patients with metastatic urothelial carcinoma. The expression of PD-L1 was usually tested as a predictive marker to anticipate the response of checkpoint inhibitor. In addition, this study showed that the expression of PD-L1 in tumor cells was significantly related to the OS for poor prognostic marker (HR, 13.42; 95% CI, 3.64 to 49.43) after adjusting the significant prognostic clinicopathological parameters in localized UTUC (p \< 0.01) ([Table 2](#t2-crt-2019-119){ref-type="table"}). The Kaplan-Meier curve of OS also supported the significantly poorer prognostic outcomes in positive PD-L1 group (n=5) than in the negative PD-L1 group (n=175) ([Fig. 2C](#f2-crt-2019-119){ref-type="fig"}). Although the number of deaths in the positive group looked small compared to the 16 deaths in the negative PD-L1 group, the proportional survival rate of PD-L1 positive was higher (60%) than the negative PD-L1 negative group (10.2%). This implies that the PD-L1 inhibitor might be an efficacious therapy, even in patients with localized UTUC who may be unsuitable candidates for surgery due to major comorbidities. The positive expression level of PD-L1 was observed in only 3.1% of the study population (n=5). The method to evaluate PD-L1 expression in urothelial cancer has not been standardized. Several antibodies have been used for different targets (e.g., tumor cell or immune cell or combine) with different targets. The current checkpoint inhibitor was approved for use only in patients with locally advanced or metastatic urothelial carcinoma as a second-line therapy after failure of first-line chemotherapy in Korea, and the cut-off point of expression level was 5% \[[@b14-crt-2019-119]\]. This is the first study to report the expression levels of PD-L1 in patients with UTUC after RNU.

The E-cadherin marker was considered as a favorable marker in both IVRFS and OS (p \< 0.05), in spite of its loss of marginal significance when presented as a continuous value of expression (p=0.051) ([Table 2](#t2-crt-2019-119){ref-type="table"}). E-cadherin is an important prognostic factor for UTUC; loss of E-cadherin expression or weak E-cadherin expression is related to IVRFS and DFS \[[@b15-crt-2019-119]\]. A recent IHC study by Cho et al. \[[@b16-crt-2019-119]\] using TMA of RNU showed the correlation between loss of E-cadherin levels and epithelial-mesenchymal transition (EMT) phenotypes such as wild type, incomplete type (loss of E-cadherin and negative for vimentin), and complete type (loss of E-cadherin and positive for vimentin). The EMT complete type was an independent prognostic factor for extra-bladder recurrence-free survival and OS, which was similar to the results of DFS and OS in this study conducted among 162 patients.

Rb loss \[[@b17-crt-2019-119]\] and c-erb \[[@b18-crt-2019-119]\] were well-known prognostic markers in upper urinary and bladder urothelial carcinoma. The loss of RB expression is a well-known invasive pathogenetic marker in bladder urothelial carcinoma, resulting in progression to muscle invasive bladder cancer from non-invasive bladder cancer, often resulting in resistance to cisplatin chemotherapy \[[@b19-crt-2019-119],[@b20-crt-2019-119]\]. However, no previous study has identified the prognostic role of the Rb tissue marker in UTUC until this study identified its unfavourable role in IVRFS (HR, 1.85) ([Table 2](#t2-crt-2019-119){ref-type="table"}). C-erbB2, another significant factor identified for the first time in UTUC, has been reported in a literature on bladder urothelial carcinoma for its prognostic role in IVRFS and its relation to histologic grade. This study supported this finding, in which the tumor grade and pathologic N stage were significantly related to the c-erbB2, marker (p \< 0.05) ([S3 Table](#SD3-crt-2019-119){ref-type="supplementary-material"}) \[[@b21-crt-2019-119],[@b22-crt-2019-119]\]. A Spanish study \[[@b23-crt-2019-119]\] using 61 TMAs of RNU showed that c-erbB2 was negatively associated with cancer-specific death and disease progression. This finding also supports our results, indicating that c-erbB2, was the only significant unfavourable risk factor (HR, 2.59) for IVRFS ([Table 2](#t2-crt-2019-119){ref-type="table"}).

The last significant HMWCK marker for DFS is a routine tissue marker with Ki-67 in bladder urothelial carcinoma, with frequent expression (\> 60%) in all invasive tumors \[[@b25-crt-2019-119],[@b26-crt-2019-119]\]. It is an urothelial carcinoma-specific marker and frequently used to distinguish between urothelial carcinoma and differentiated prostatic carcinoma that mimics urothelial carcinoma \[[@b10-crt-2019-119]\].

This study had some limitations besides the retrospective design which included only few patients with UTUC and the arbitrary binary cut-off points of expression levels. Some other important prognostic clinicopathological parameters such as intraoperative complication was not considered in this study due to the absence of the Clavien grade 3 or 4 complication, whereas the large-numbered Connolly and Rochester study demonstrated the safety of nephroureterectomy procedure with a report of only 4% of Clavien grade 3 or 4 complications \[[@b29-crt-2019-119]\]. These limitations might interfere with the significance of this study. More important markers associated with basal and luminal urothelial carcinoma of the bladder, which were not examined in this study, should be considered in future trials using larger cohorts of UTUC. However, this 27 IHC analytic report will help determine the molecular diagnostic and predictive biomarkers of rare UTUC, similar to those of bladder urothelial carcinoma. These might be used as baseline data to further validate the therapeutic roles of currently used targeted agents such as fibroblast growth factor receptor 3, human epidermal growth factor receptor 2, and PD-1/PD-L1 in bladder urothelial carcinoma.

In conclusion, this study identified several significant prognostic tissue markers in UTUC TMAs, which would help better understand the pathogenesis and prognostic outcomes of UTUC. Some of the tissue markers identified in this study were the first reported prognostic factors for UTUC after RNU.
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###### 

Expression level of each 27 tissue markers using immunohistochemistry
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The specifications of each antibody clone used in the study
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Univariable Cox proportional hazard model for clinicopathological variables

###### 

Multivariable Cox proportional hazard model of continuous expression level for BRFS, DPFS, and OS

![Immunohistochemistry staining of five significant tissue markers according to their negative and positive expression: c-erb (×35 and ×100) (A), E-cadherin (×35 and ×100) (B), programmed cell death 1 ligand (×35 and ×100) (C), cyclin D1 (×35 and ×100) (D), and high-molecular-weight heparin (×35 and ×100) (E).](crt-2019-119f1){#f1-crt-2019-119}

![Survival curves associated with tissue markers for intravescial recurrence-free survival (A), disease-free survival (B), and overall survival (C). HR, hazard ratio; CI, confidence interval; Rb, retinoblastoma; HMWCK, high-molecular-weight heparin.](crt-2019-119f2){#f2-crt-2019-119}

###### 

Baseline characteristics

  Characteristic                               No. (%) (n=162)
  -------------------------------------------- ------------------
  **Follow-up duration, median (range, mo)**   53.4 (3.6-176.5)
  **Age, mean±SD (yr)**                        66.5±10.4
  **Body mass index, mean±SD (kg/m^2^)**       24.0±3.4
  **Sex**                                      
   Male                                        119 (73.5)
   Female                                      43 (26.5)
  **Hypertension**                             74 (45.7)
  **Diabetes**                                 22 (13.6)
  **Other**                                    63 (38.9)
  **ASA score**                                
   1                                           34 (22.4)
   2                                           105 (69.1)
   3                                           13 (8.5)
  **Nephroureterectomy method**                
   Open                                        90 (55.6)
   Laparoscopy                                 72 (44.4)
  **Previous history**                         
   No                                          111 (68.5)
   Previous bladder tumor history              46 (28.4)
   Concomitant bladder tumor history           5 (3.1)
  **Intravesical instillation**                59 (36.4)
  **Tumor location**                           
   Renal pelvis                                65 (40.4)
   Proximal                                    7 (4.4)
   Mid                                         18 (11.2)
   Distal                                      38 (23.6)
   More than two sites                         33 (20.5)
  **Tumor grade**                              
   I                                           5 (3.3)
   II                                          55 (36.2)
   III                                         92 (60.5)
  **ISUP**                                     
   Low                                         32 (21.1)
   High                                        120 (78.9)
  **Pathologic T category**                    
   Ta                                          8 (5.0)
   T1                                          25 (15.7)
   T2                                          40 (25.2)
   T3                                          76 (47.8)
   T4                                          8 (5.0)
   CIS only                                    2 (1.3)
  **Pathologic N category**                    
   Nx                                          96 (59.3)
   N0                                          53 (32.7)
   N1                                          10 (6.2)
   N2                                          3 (1.9)
  **Tumor size (cm)**                          
   0-1.5                                       13 (8.1)
   1.5-2.5                                     27 (16.9)
   \> 2.5                                      120 (75.0)
  **Adjuvant chemotherapy**                    72 (44.4)
  **Bladder recurrence**                       58 (35.8)
  **Disease progression**                      48 (29.6)
  **Cause-specific death**                     
   Upper tract                                 4 (21.1)
   Bladder                                     2 (10.5)
   Others                                      13 (68.4)

SD, standard deviation; ASA, American Society of Anesthesiologists; ISUP, International Society of Urologic Pathologists; CIS, carcinoma *in situ*.

###### 

Univariable and multivariable Cox proportional hazard model of high or low expression level for IVRFS, DFS, and OS after adjusted by significant prognostic clinicopathologic variables for each survival

                                                                               Cut-point   No. (n=162)   Event (%)   Univariable         Multivariable                        
  ---------------------------------------------------------------------------- ----------- ------------- ----------- ------------------- --------------- -------------------- ----------
  **IVRFS^[a)](#tfn1-crt-2019-119){ref-type="table-fn"}^ (n=162, event=58)**                                                                                                  
   C-erb                                                                                                                                                                      
    Low                                                                        0           141           52 (36.9)   1 (reference)                       1 (reference)        
    High                                                                       \> 0        21            6 (28.6)    0.74 (0.32-1.72)    0.483           2.59 (1.05-6.39)     0.039
   C-myc                                                                                                                                                                      
    Low                                                                        ≤ 30        82            35 (42.7)   1 (reference)                       1 (reference)        
    High                                                                       \> 30       80            23 (28.8)   0.56 (0.33-0.95)    0.031           0.88 (0.52-1.51)     0.650
   E-cadherin                                                                                                                                                                 
    Low                                                                        ≤ 270       119           45 (37.8)   1 (reference)                       1 (reference)        
    High                                                                       \> 270      43            13 (30.2)   0.69 (0.37-1.27)    0.231           0.49 (0.26-0.91)     0.025
   ERCC1                                                                                                                                                                      
    Low                                                                        ≤ 130       63            31 (49.2)   1 (reference)                       1 (reference)        
    High                                                                       \> 130      99            27 (27.3)   0.5 (0.3-0.83)      0.008           1.06 (0.63-1.8)      0.818
   Rb loss                                                                                                                                                                    
    Low                                                                        ≤ 20        66            22 (33.3)   1 (reference)                       1 (reference)        
    High                                                                       \> 20       96            36 (37.5)   1.21 (0.71-2.06)    0.478           1.85 (1.07-3.19)     0.028
   VEGF                                                                                                                                                                       
    Low                                                                        ≤ 170       75            35 (46.7)   1 (reference)                       1 (reference)        
    High                                                                       \> 170      87            23 (26.4)   0.45 (0.27-0.77)    0.003           0.66 (0.39-1.13)     0.132
  **DFS^[b)](#tfn2-crt-2019-119){ref-type="table-fn"}^ (n=162, event=48)**                                                                                                    
   COX2                                                                                                                                                                       
    Low                                                                        \< 300      110           27 (24.6)   1 (reference)                       1 (reference)        
    High                                                                       ≥ 300       52            21 (40.4)   1.9 (1.08-3.37)     0.027           1.55 (0.87-2.75)     0.137
   Cyclin D1                                                                                                                                                                  
    Low                                                                        ≤ 40        81            17 (21.0)   1 (reference)                       1 (reference)        
    High                                                                       \> 40       81            31 (38.3)   2.07 (1.15-3.75)    0.016           2.16 (1.19-3.94)     0.011
   HMWCK                                                                                                                                                                      
    Low                                                                        ≤ 130       88            34 (38.6)   1 (reference)                       1 (reference)        
    High                                                                       \> 130      74            14 (18.9)   0.39 (0.21-0.72)    0.003           0.42 (0.22-0.79)     0.007
   PD-L1                                                                                                                                                                      
    Low                                                                        0           157           45 (28.7)   1 (reference)                       1 (reference)        
    High                                                                       \> 0        5             3 (60.0)    4.05 (1.25-13.16)   0.020           2.26 (0.69-7.37)     0.178
  **OS^[c)](#tfn3-crt-2019-119){ref-type="table-fn"}^ (n=162, event=19)**                                                                                                     
   E-cadherin                                                                                                                                                                 
    Low                                                                        \< 150      85            14 (16.5)   1 (reference)                       1 (reference)        
    High                                                                       \> 150      77            5 (6.5)     0.37 (0.13-1.02)    0.055           0.34 (0.12-0.94)     0.038
   PD-L1                                                                                                                                                                      
    Low                                                                        0           157           16 (10.2)   1 (reference)                       1 (reference)        
    High                                                                       \> 0        5             3 (60.0)    17.2 (4.68-63.18)   \< 0.001        13.42 (3.64-49.43)   \< 0.001

IVRFS, intravescial recurrence-free survival; DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ERCC1, ERCC excision repair 1; Rb, retinoblastoma; VEGF, vascular endothelial growth factor; COX2, cytochrome coxidase II; HMWCK, high-molecular-weight heparin; PD-L1, programmed cell death 1 ligand.

Adjusted for intravesical instillation in multivariable bladder recurrence-free survival model,

Adjusted for intravesical instillation and pTstage in multivariable progression-free survival model,

Adjusted for pTstage in multivariable OS model.

###### 

Univariable and multivariable Cox proportional hazard model of high or low expression level for BRFS, DPFS, and OS in only patients with no prior or concurrent bladder cancer history

                                                                              Cut-point   No. (n=111)   Event (%)   Univariable          Multivariable                       
  --------------------------------------------------------------------------- ----------- ------------- ----------- -------------------- --------------- ------------------- -------
  **BRFS^[a)](#tfn4-crt-2019-119){ref-type="table-fn"}^ (n=111, event=36)**                                                                                                  
   C-erb                                                                                                                                                                     
    Low                                                                       0           95            30 (31.6)   1 (reference)                        1 (reference)       
    High                                                                      \> 0        16            6 (37.5)    1.24 (0.52-2.99)     0.629           2.55 (1.01-6.41)    0.047
   C-myc                                                                                                                                                                     
    Low                                                                       ≤ 30        58            23 (39.7)   1 (reference)                        1 (reference)       
    High                                                                      \> 30       53            13 (24.5)   0.54 (0.27-1.06)     0.072           1.02 (0.50-2.05)    0.964
   E-cadherin                                                                                                                                                                
    Low                                                                       ≤ 270       84            27 (32.1)   1 (reference)                        1 (reference)       
    High                                                                      \> 270      27            9 (33.3)    1.07 (0.50-2.27)     0.867           1.28 (0.60-2.76)    0.522
   ERCC1                                                                                                                                                                     
    Low                                                                       ≤ 130       42            17 (40.5)   1 (reference)                        1 (reference)       
    High                                                                      \> 130      69            19 (27.5)   0.61 (0.32-1.17)     0.138           1.23 (0.62-2.42)    0.554
   Rb                                                                                                                                                                        
    Low                                                                       ≤ 20        43            12 (27.9)   1 (reference)                        1 (reference)       
    High                                                                      \> 20       68            24 (35.3)   1.37 (0.68-2.75)     0.375           1.74 (0.85-3.54)    0.129
   VEGF                                                                                                                                                                      
    Low                                                                       ≤ 170       47            19 (40.4)   1 (reference)                        1 (reference)       
    High                                                                      \> 170      64            17 (26.6)   0.57 (0.30-1.11)     0.097           0.97 (0.50-1.89)    0.925
  **DPFS^[b)](#tfn5-crt-2019-119){ref-type="table-fn"}^ (n=111, event=34)**                                                                                                  
   COX2                                                                                                                                                                      
    Low                                                                       \< 300      71            18 (25.4)   1 (reference)                        1 (reference)       
    High                                                                      300         40            16 (40.0)   1.85 (0.94-3.63)     0.074           1.53 (0.77-3.01)    0.223
   Cyclin D1                                                                                                                                                                 
    Low                                                                       ≤ 40        53            12 (22.6)   1 (reference)                        1 (reference)       
    High                                                                      \> 40       58            22 (37.9)   2.04 (1.01-4.14)     0.048           2.33 (1.14-4.75)    0.020
   HMWCK                                                                                                                                                                     
    Low                                                                       ≤ 130       59            22 (37.3)   1 (reference)                        1 (reference)       
    High                                                                      \> 130      52            12 (23.1)   0.50 (0.25-1.02)     0.057           0.48 (0.24-0.99)    0.047
   PD-L1                                                                                                                                                                     
    Low                                                                       0           106           31 (29.3)   1 (reference)                        1 (reference)       
    High                                                                      \> 0        5             3 (60.0)    4.05 (1.22-13.48)    0.023           2.32 (0.69-7.74)    0.173
  **OS^[c)](#tfn6-crt-2019-119){ref-type="table-fn"}^ (n=111, event=17)**                                                                                                    
   E-cadherin                                                                                                                                                                
    Low                                                                       ≤ 150       57            12 (21.1)   1 (reference)                        1 (reference)       
    High                                                                      \> 150      54            5 (9.3)     0.41 (0.14-1.15)     0.090           0.35 (0.12-0.99)    0.048
   PD-L1                                                                                                                                                                     
    Low                                                                       0           106           14 (13.2)   1 (reference)                        1 (reference)       
    High                                                                      \> 0        5             3 (60.0)    13.82 (3.64-52.49)   \< 0.001        10.8 (2.83-41.25)   0.001

BRFS, bladder recurrence-free survival; DPFS, disease progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; C-erb, epidermal growth factor receptor; ERCC1, ERCC excision repair 1; Rb, retinoblastoma; VEGF, vascular endothelial growth factor; COX2, cytochrome c oxidase II; HMWCK, high-molecular-weight heparin; PD-L1, programmed cell death 1 ligand.

Adjusted for intravesical instillation in multivariable BRFS model,

Adjusted for age, intravesical instillation and pTstage in multivariable progression-free survival model,

Adjusted for pTstage in multivariable OS model.
